Navigation Links
Actos Lawsuits Move Forward Following Latest Status Conference in Federal Actos Bladder Cancer Litigation
Date:8/31/2013

New York, New York (PRWEB) August 31, 2013

Thousands of Actos lawsuits (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) filed on behalf of patients who developed bladder cancer that may be related to long-term use of the Type 2 diabetes drug continue to move forward in a multidistrict litigation underway in U.S. District Court, Western District of Louisiana. According to court documents, the most recent Status Conference in the litigation was convened on August 22, 2013, at which time a number of issued were addressed, including the status of state and federal Actos lawsuits, and preparations for the proceeding’s bellwether trials. More than 2,500 Actos bladder cancer claims are currently pending in the Western District of Louisiana, where the first trials are scheduled to begin in January. (In re: Actos Product Liability Litigation, MDL No. 2299)

“Our Firm receives inquiries on a regular basis from individuals seeking to file an Actos bladder cancer lawsuit. We are not at all surprised that the number of claims filed in Louisiana has surpassed 2,500, and look forward to additional progress in the proceeding in the coming months,” says Bernstein Liebhard LLP, nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to patients who developed bladder cancer after using the medication for an extended period of time.

Actos Bladder Cancer Lawsuits
All of the lawsuits pending in the Western District of Louisiana accuse Takeda Pharmaceuticals of concealing knowledge that use of the Type 2 diabetes treatment was associated with an increased risk of bladder cancer, and failing to provide adequate warnings to patients and doctors regarding this risk. The litigation was established in December 2011, after the U.S. Food & Drug Administration (FDA) warned the previous June that use of Actos for more than one year had been associated with a significant increase in the risk for bladder cancer. According to Bloomberg.com, Actos was also pulled from the market in Germany and France that month because of its association with bladder cancer.*

Additional Actos bladder cancer lawsuits have also been filed in various federal courts around the country. In April, the nation’s first trial involving Actos bladder cancer allegations ended with a Los Angeles Superior Court jury awarding $6.5 million to a plaintiff who was diagnosed with the disease after taking Actos for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

Actos patients who were diagnosed with bladder cancer may be entitled to compensation for medical bills, lost wages and other damages related to their illness. Learn More about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb11079665.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Oregon Man Developed Bladder Cancer Brought on by Years of Ingesting Diabetes Drug Actos, Alleges Lawsuit Filed by Parker Waichman LLP
2. Florida Woman Developed Bladder Cancer After Taking Actos to Treat her Type II Diabetes, Alleges Lawsuit Filed by Parker Waichman LLP
3. Years of Ingesting Diabetes Drug Actos Caused Florida Man to Develop Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
4. Actos Lawsuits Alleging Bladder Cancer Update: Resource4thePeople Reports Judge Continues to Move Multidistrict Litigation Forward
5. Organic Valley Presents Lactose Free Whole Milk and Lactose Free Half & Half
6. Actos Lawsuit – Status Conference Convened in Federal Actos Bladder Cancer Multidistrict Litigation, Bernstein Liebhard LLP Reports
7. Actos Lawsuit News: More Than a Dozen Lawsuits Filed in West Virginia, Rottenstein Law Group LLP Reports
8. Actos Bladder Cancer Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Actos Litigation
9. Actos Diabetes Medication Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
10. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Actos Bladder Cancer Litigation
11. Texas Man Suffering from Bladder Cancer Because of Actos Use, Alleges Lawsuit Filed by Parker Waichman LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... 2017 , ... Miro is the ultimate smart media center that offers a ... TV shows and much more apps for user exploration. Its innovative acoustic design with ... 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi connection ...
(Date:2/27/2017)... ... 27, 2017 , ... Sunshine Coast Health Centre (SCHC), one ... at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered ... Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond a ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... New Jersey ... rates, among all types and genders. And the need for advanced services is growing. ... and its top-rated cancer care program, in collaboration with their non-profit partners in their ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is ... the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 ... 17025:2005 is the globally recognised standard that sets out requirements for the technical ...
(Date:2/26/2017)... ... 2017 , ... IndustryArchive.Org . is announcing a new way for B2B ... now only pay for B.A.N.T. quality sales leads based on the Sellers decision to ... new reality that B2B buyers are controlling the sales process via the Internet and ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017   Royal Philips (NYSE: ... leader in health technology, today announced 510(k) clearance ... to market its ElastQ Imaging capability, further expanding ... systems. ElastQ Imaging enables simultaneous imaging of tissue ... for the diagnosis of various liver conditions. With ...
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... RGN-137, GtreeBNT Co., Ltd., received a positive response ... clinical trial design for RGN-137 to treat epidermolysis ... gel that incorporates Thymosin beta 4 ("Tß4") as ...
(Date:2/27/2017)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced ... President and Chief Executive Officer (CEO) and member of the ... Richard Love , interim President and CEO who will ... Craig has over 20 years of experience in hematology, oncology ... Europe . "On behalf of CTI BioPharma,s ...
Breaking Medicine Technology: